Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up […]
What do popular Stanley insulated cups have in common with two pharma migraine brands? They’re all transformational digital brands, according to new research out this week. The annual study by Trinity Life Sciences’ TGaS Advisors […]
DUBLIN, Dec. 1, 2023 /PRNewswire/ — The “DUPIXENT Drug Insight and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. DUPIXENT’s potential as a game-changer extends further with its invention through Regeneron’s proprietary […]
Two years ago, Endo featured a bent carrot in an ad campaign promoting Xiaflex as a treatment for the condition. Click here to view original post
The upgrade follows four ratings downgrades over the past two years and reflect ongoing improvements. Click here to view original post
Tharimmune closes $11M in public offering: The company, which is developing therapies that aim to treat rare, inflammatory, and oncologic conditions, announced Thursday that it sold 11 million shares of common stock for $1 per […]
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we talk about Pfizer’s obesity woes, how J&J… Click here to view original […]
Pfizer is stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial. Click here to view original post
Pfizer cans twice-daily oral obesity program after half of patients leave trial while once daily continues ntaylor Fri, 12/01/2023 – 07:57 Click here to view original post
Camille Bedrosian → With Amylyx Pharmaceuticals’ ALS drug in full commercial swing, the Massachusetts startup has found a replacement for its chief medical officer. Camille Bedrosian will join the company from Ultragenyx, taking the place […]
Copyright © 2023 Biotech Networks, LLC
